Bayesian Capital Management, LP Nektar Therapeutics Transaction History

Bayesian Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$2.03 - $4.28 $14,006 - $29,532	6,900 Added 22.77%	37,200 $84,000
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.14 $157,776 - $266,766	-51,900 Reduced 63.14%	30,300 $97,000
Q2 2022 Aug 15, 2022	BUY	$3.17 - $6.17 $260,574 - $507,174	82,200 New	82,200 $312,000
Q2 2021 Aug 13, 2021	SELL	$16.52 - $20.4 $227,463 - $280,887	-13,769 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$16.56 - $25.46 $63,938 - $98,301	-3,861 Reduced 21.9%	13,769 $275,000

Q4 2020 Feb 12, 2021	BUY	$15.77 - $19.03 $278,025 - $335,498	17,630 New	17,630 $300,000
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $604,398 - $890,986	-13,009 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $256,410 - $579,070	5,544 Added 74.27%	13,009 $635,000
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $455,469 - $860,471	-7,935 Reduced 51.53%	7,465 $793,000
Q4 2017 Feb 12, 2018	BUY	$23.02 - $60.5 $354,508 - $931,700	15,400	15,400 $920,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.